Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer - Trial NCT06356155
Access comprehensive clinical trial information for NCT06356155 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Michigan Rogel Cancer Center and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Michigan Rogel Cancer Center
Timeline & Enrollment
Phase 2
Oct 01, 2024
Jul 01, 2027
Primary Outcome
Efficacy of the combination of enfortumab vedotin and pembrolizumab as neoadjuvant therapy in cisplatin-eligible patients based off pathological response
Summary
This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of
 enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade
 localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed
 eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy)
 followed by adjuvant pembrolizumab.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06356155
Non-Device Trial